ClearPoint Neuro price target raised to $30 from $17 at Lake Street

Lake Street analyst Frank Takkinen raised the firm’s price target on ClearPoint Neuro (CLPT) to $30 from $17 and keeps a Buy rating on the shares. While shares have had a meaningful move, the firm still does not think investors “fully appreciate” the potential of the partner business, says the analyst, who expects a basket of approved combo-therapies to be on the market over time and sees this providing “multiple growth opportunities” for ClearPoint.